SLAS2017
04 February 2017 - 08 February 2017
World-Class Podium Presentations Offer SLAS2017 Participants a Wide Range of Learning Opportunities
SLAS2017 offers participants a world-class scientific program that showcases the top laboratory science and technology podium presentations from industry leaders around the world. Each podium presentation is hand selected by the SLAS2017 Scientific Program Committee from hundreds of abstract submissions. Presentations offer SLAS2017 participants compelling content and new perspectives on emerging laboratory technologies from a broad range of industries, including drug discovery and development, informatics, clinical diagnostics, food and agricultural sciences, forensics and security sciences, petrochemicals and energy, and consumer products.
A complete schedule of podium presentations and conference activities will be available in fall 2016.
SLAS2017 Educational Tracks
The SLAS2017 scientific program features seven educational tracks:
Advances in Bioanalytics, Biomarkers and Diagnostics
Assay Development and Screening
Automation and High-Throughput Technologies
Cellular Technologies
Data Analysis and Informatics
Drug Target Strategies
Micro- and Nanotechnologies
Walter E. Washington Conference Center, Washington DC, USA
http://slas2017.org/index.cfm
Parallel Trade
06 February 2017 - 07 February 2017
According to the European Federation of Pharmaceutical Industries and Associations, parallel trade was estimated to amount to € 5,589 million (value at ex–factory prices) in 2014. The fragmentation of the EU pharmaceutical market has resulted in a lucrative year for parallel trade. Factors such as foreign exchange fluctuations and legal battles on trademarks and counterfeit medicines are continuously shifting the European market dynamics.
With Brexit and the new EU Falsified Medicine Directive, what does the future hold for parallel trade? This event will discuss short term versus long term concerns of pharma manufacturers, regulators, as well as parallel traders. They will engage in an interactive debate and discuss how to keep abreast of the current trends and how to overcome all challenges.
Holiday Inn Kensington Forum, London, UK
https://www.smi-online.co.uk/pharmaceuticals/uk/parallel-trade?utm_medium=www.parallel-trade.com&utm_source=P-195&utm_campaign=els
9th Immunotherapeutics & Immunomonitoring Conference
06 February 2017 - 07 February 2017
The immune system plays a central role not only in fighting infections, but also in many diseases and medical conditions, including cancer. Studies of the immune system has led to significant findings in many fields of medicine and biology, which has yielded the discovery of novel and unique substances and reagents that are now widely used for diagnosing, evaluating, and treating different malignant diseases. The development of prophylactic and therapeutic vaccines, and innovative combinatorial immunotherapeutic approaches, has substantially decreased mortality, increased life expectancy, improved life expectancy and improved the well-being of the millions of patients.
Leading scientific and clinical experts from academia and industry will present the latest findings and developments in the exciting area of immunotherapeutics and immunomonitoring. New immunological concepts with clinically translational implications will be discussed, along with evaluations of novel drug targets and therapeutic approaches, the role of biomarkers in immunomonitoring, and the latest data on combinatorial treatments in the clinic.
Network with colleagues to discuss updates on state-of-the-art immunomonitoring, novel strategies to identify and validate biomarkers predictive for clinical efficacy, novel strategies to identify and clinically develop synergistic combination therapies, and the outlook on novel druggable targets for immunotherapy.
Hard Rock Hotel, San Diego, CA, USA
https://www.gtcbio.com/conferences/immunotherapeutics-immunomonitoring-overview
3rd Protease Inhibitors in Drug Discovery Conference
08 February 2017 - 09 February 2017
We are pleased to announce the 3rd Protease Inhibitors in Drug Discovery Conference, to be hosted by GTCbio on February 8-9, 2017 in San Diego, CA. Though protease inhibitors hold great therapeutic promise in areas such as inflammation, cardiovascular diseases, and cancer, researchers in the field are still overcoming the challenge of specificity for drug design.
This meeting will provide a forum for scientists from both industry and academia to share recent advances in protease inhibitor research, from biological functions to translational aspects for drug discovery. Speakers will cover topics such as regulation of proteases by exosites, drug design of protease inhibitors, membrane-associated proteolysis, and many more. In addition to cutting-edge scientific presentations, attendees will be able to form new connections during dedicated networking sessions.
We hope to see you there!
Hard Rock Hotel San Diego, San Diego, CA, USA
https://www.gtcbio.com/conferences/protease-inhibitors-drug-discovery-overview
12th Annual Biomarkers Congress 2017
21 February 2017 - 22 February 2017
Attended by over 250 participants from the pharmaceutical industry, the congress offers a balance of scientific presentations and unprecedented networking opportunities. In line with the current industry trends, day one of the congress focusses on the identification of safety biomarkers for the detection of drug-induced toxicity; using biomarkers through the various stages of R&D and the translation of biomarkers from the discovery to the exploration stages. The companion diagnostics & personalised medicine stream features the latest updates in companion diagnostics developments, regulatory updates and the future of targeted therapy, precision medicine & patient self-monitoring in healthcare.
tbc Manchester, UK
http://www.biomarkers-congress.com/
3D Cell Culture 2017
22 February 2017 - 23 February 2017
Following the success of the sell-out Cell Based Assay series, SMi Group has launched its inaugural conference on 3D Cell Culture which takes place on the 22nd and 23rd of February 2017 in London. The agenda, as well as registration, is now live on www.3D-cellculture.com.
With a focus on clinical successes and emerging technologies, the conference will showcase how 3D Cell Culture has revolutionized drug discovery and toxicity screening, as well as how it is emerging as an invaluable tool in stem cell research and regenerative medicine.
The event will also highlight exciting opportunities and latest innovations, spheroid and organoid techniques, as well as key developments in 3D and 4D bio-printing, microfluidics, CRISPR and the ongoing debate of 2D vs 3D cell culture. Expert speakers include AstraZeneca, GSK, Lonza, MHRA, Novartis, Sanofi, etc.
Copthorne Tara Hotel, Kensington, London UK
https://www.smi-online.co.uk/pharmaceuticals/uk/3D-Cell-Culture
RNA Therapeutics 2017
22 February 2017 - 23 February 2017
SMi’s 8th annual RNA Therapeutics conference will feature a mix of case study-led presentations, panel debates, interactive workshops and keynote addresses tailored for an audience of professionals and research scientists looking to develop and commercialise novel RNA therapeutics and delivery systems. This exciting programme for 2017 will showcase new developments through clinical and pre-clinical results in topics such as: messenger RNA-based therapeutics, anti-sense oligonucleotides and new sites for RNA silencing.
Join us next February to expand your scientific horizons on emerging concepts in nanoparticle delivery systems, small activating RNA and 3rd generation antisense technology. Plus, we’ll be honing in on under-met areas such as targeted delivery beyond the liver, and offering regulatory guidance on the reporting of clinical data through an exclusive MHRA keynote.
Featured speakers include:
• Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, MiNA Therapeutics
• John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, MHRA
• Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
• Bo Rode Hansen, Global Head of RNA Therapeutics, Roche
• Nicole Meisner-Kober, Senior Investigator, RNA Biology, Novartis Institutes for Biomedical Research
• Steve Hood, Director, Bioimaging, GSK
• David Giljohann, CEO, Exicure
• Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals Inc
• Amotz Shemi, CEO, Silenseed
• Sanyogitta Puri, Associate Principal Scientist, AstraZeneca
Copthorne Tara Hotel, Kensington, London UK
https://www.smi-online.co.uk/pharmaceuticals/uk/conference/rna-therapeutics?utm_source=P-197&utm_medium=2017rna1.asp&utm_campaign=GOTO